Our latest COVID-19 information - full Autumn programme of webinars now in place

Pharmaceutical Regulatory Affairs in Asia Training Course

This seminar will provide an overview of the key areas of pharmaceutical regulatory affairs in Asia including, China, Hong Kong SAR, Brunei, the Philippines, India, Indonesia, Malaysia, Singapore, Thailand, Cambodia, Laos, Vietnam, Taiwan, Korea, Japan

7-9 Apr 2021

& 14-16 Apr 2021

Book now


Course Overview

The pharmaceutical market in Asia is growing at a rapid pace and presents both opportunities and challenges to those wishing to work in the region. Rather than a single market, Asia is a collection of different markets, each with their own regulatory processes, although harmonisation exists within the ASEAN countries.

This seminar will provide a practical overview of the key areas of pharmaceutical regulatory affairs in Asia, including India, and will cover all important aspects of gaining and maintaining a successful marketing authorisation within the region.

The programme will include:
  • Discussion of underlying official regulatory sources
  • An interpretation of practical aspects
  • An overview of the requirements for local manufacturing
  • Recent developments
  • Harmonisation initiatives
  • An update and wider knowledge of regulatory affairs in Asia
  • The opportunity to exchange experiences with other delegates

Benefits of attending:

  • Gain an overview of key Asian markets
  • Discuss outlines of company and product registration
  • Understand the application process
  • Assess the impact of recent regulatory developments in the region
  • Discuss harmonisation initiatives including ASEAN opportunities
  • Understand how Japan fits in the Asian regulatory landscape
  • Discover general, country-specific and regional requirements

Who should attend

This seminar will be of particular interest to all those who need to learn about successful marketing authorisation applications and in-market regulatory compliance, whether as an introductory or a refresher course.

Previous delegates have included:
  • Scientists and technical staff in
    • Regulatory affairs
    • Registration departments
  • Medical directors


Day 1: China, Hong Kong SAR, Introduction to ASEAN, Brunei and the Philippines
Day 2: India, Indonesia, Malaysia, Singapore, Thailand, Vietnam
Day 3: Taiwan, Korea, brief comparison with Japan, ASEAN harmonisation

Regional presentations covering:

  • The markets
    • Brief commercial and cultural background
    • Importance of major markets
  • Company and product registration
    • Regulations and guidelines
    • Drug classification systems
    • Site registration
    • New products
    • Line extensions
    • Labelling changes
    • Sourcing changes
    • Registration samples
    • Certificates/legalisation
  • Application process
    • Committees/meetings
    • New applications
    • Variations
    • Renewals/re-registration
  • Recent regulatory developments
    • Influences and changes: national and regional
    • The latest regulatory developments in the region

Harmonisation Initiatives

  • ASEAN Opportunities

A Brief comparison of how Japan fits into the Asian regulatory landscape


Monica Dressler-Meyer (More...)

Mónica Dressler-Meyer is DRA Manager based in Switzerland with many years of regulatory experience. She has spent many years in DRA working with different pharmaceutical companies with responsibility for Asia Pacific and lately also for development activities in other regions. Prior to this, she worked at F. Hoffmann-La Roche in Switzerland where she gained several years’ experience in industry basics and pre-clinical research. She has a Degree in Chemistry and Biochemistry from Basel University.

Alan Chalmers (More...)

Dr Alan Chalmers is a pharmacist with over 35 industrial experiences mainly in the field of pharmaceutical regulatory affairs. A graduate of Strathclyde University in Glasgow with a B.Sc. in Pharmacy with specialisation in Pharmaceutical Technology, his Ph.D. at Manchester University was in Pharmaceutical Formulation. From 1975-1978 he was Development Officer and Clinical Trials Pharmacist of Allen & Hanburys (part of the then Glaxo group). In 1978 he joined Ciba-Geigy in DRA. Over 20 years were spent with Ciba-Geigy/CIBA/Novartis in all aspects of regulatory affairs including head of a group company DRA in Canada and for many years as Head of Pharma International regulatory affairs.
He has been consultant to the IFPMA, WHO and other international bodies and was Chairman of the Organising Committee of the initial IFPMA Asian Regulatory Conferences in Hong Kong and Singapore and Rapporteur to the more recent conferences in China and Malaysia.
Since 1998 he has been an independent regulatory consultant and is Director of his own consultancy company Pharma International in Switzerland. He has also been director of two UK and Swiss registered pharmaceutical companies with specialised responsibility for international regulatory strategy. More recently as accredited by Swissmedic, Dr. Chalmers is a Qualified Person supporting several Swiss pharmaceutical companies trading internationally with pharmaceuticals and medical devices.
He is published, and his publications include a textbook on International Pharmaceutical Registration, Active Pharmaceutical Ingredients and as Swiss correspondent to the Regulatory Affairs Journals Pharma and Medtech. Since 2012 he has been a member of the Editorial Board, Scrip Regulatory Affairs.

Book now

Book now

7-9 Apr 2021
Live webinar
7-9 Apr 2021
Live webinar
GBP 1,249.00
EUR 1,809.00
USD 2,056.00
Until 24 Feb 21*
Enrol now
to attend
Live webinar
14-16 Apr 2021
Face-to-face, (venue not yet confirmed)
14-16 Apr 2021
(venue not yet confirmed)
GBP 1,549.00
EUR 2,169.00
USD 2,416.00
Until 3 Mar 21*
Enrol now
to attend
(venue not yet confirmed)
  • 3 days of classroom-based training
  • Meet presenters and fellow attendees in person
  • Lunch and refreshments provided
  • Download documentation and certification of completion
  • Fair transfer and cancellation policy

Learn more about our face-to-face and webinar training formats.

* Note the early booking discount cannot be combined with any other offers or promotional code

Customised in-house training

We can customise this course to meet the requirements of your organisation and deliver it at your location and/or online.

Contact us

You may also be interested in

Previous customers include...

  • Biocompatibles UK Ltd
  • BioGaia AB
  • BOC Limited member of Linde Group
  • Bracco Imaging SpA
  • Business Monitor International Ltd
  • Chiron S.r.l
  • Dr Willmar Schwabe GmbH & Co
  • F. Hoffmann-La Roche Ltd
  • Galderma International
  • GE Healthcare Ltd
  • Gilead Sciences International Ltd
  • GlaxoSmithKline
  • GlaxoSmithKline Vaccines & Diagnostics s.r.l.
  • Grunenthal GmbH
  • Guerbet
  • Ipsen Pharma SAS
  • Jadran Galenski Laboratorij d.d.
  • Merck Kga A - Werk Darmstadt
  • MSD
  • Mundipharma Laboratories GmbH
  • Novo Nordisk A/S
  • Pharmacia AB - Helsingborg
  • Sanofi Synthelabo Recherche
  • Sanofi-Aventis
  • Smith & Nephew Wound Management
  • STADA Arzneimittel AG
  • Valeant Pharma Switzerland GmbH

A good overview about RA in Asia - the classes given by Monica were a joy to attend!

Andrea Gießmann, Regulatory Affairs Manager, HELM AG, Apr 19

Very good, and extensive knowledge in the area, very impressive. Very, very good course, learnt a lot.

Pernille Træholt, Head of Regulatory Affairs and QA, Pharmanovia A/S, Apr 19

I think the content is very good, even though very extensive

Karina Kück, Graduate Regulatory Professional, H. Lundbeck A/S, Apr 19

Both are very experienced on these countries with high knowledge on the regulatory aspects. I can say that my opinion of the course is very positive.

Sonia Dias, Regulatory Affairs Officer, BIAL - Portela & Ca, S.A., Apr 19

high speed and a lot to take in. But very useful information

Christine Eliasson, Senior Regulatory Manager, BioGaia AB, Apr 18

The course was full of interesting information

Tanja Hammen, Manager Regulatory Affairs, Engelhard Arzneimittel GmbH & Co. KG, Apr 18

Everything was very professional and well organised

Anca-Maria Perian, Regulatory Affairs Manager International, Cesra Arzneimittel GmbH & Co. KG, Apr 18

Great speakers, great over 3 days, great knowledge

Marta Parmar, ‎Regulatory CMC Lead, Global Emerging Markets, Biogen International GmbH, Apr 18

Monica is brilliant love her enthusiasm and the way she manages the presentation

Tania Castanheira, Reg Affairs Associate 1, Gilead Sciences International Ltd, Apr 17

Really good. I do not come from a regs background and some of the content went over my head however even without any prior knowledge I found the course very helpful and could take a lot of information away with me. It was all pitched correctly

Erika Ravitz, Artwork Co-ordinator, Eisai Manufacturing Limited, Apr 17

Excellent contents of regulatory requirements in the region with very good ideas on new requirements and challenges

Salah Chettibi, Regulatory Affairs Manager, Kyowa Kirin International plc, Apr 17

I was pleased with the course in terms of content, presentation and speakers

Aurelia Signorelli, Regulaotry Affairs Manager, Specialised Therapeutics Australia Pty Ltd, Apr 17